• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Long-term disease control and safety with the anti-CCR4 antibody mogamulizumab: Post-hoc analyses from the MAVORIC trial of patients with previously treated cutaneous T-cell lymphoma.

作者信息

Bagot Martine, Dalle Stéphane, Sokol Lubomir, Tsianakas Athansios, Musiek Amy, Ortiz-Romero Pablo L, Poligone Brian, Duvic Madeleine, Elmets Craig, Leoni Mollie, Dwyer Karen, Ito Takahiro, Herr Fiona, Kim Youn H

机构信息

Hôpital Saint Louis, APHP, Inserm U976, Université Paris Cité, Paris, France.

Hospices Civils de Lyon, Claude Bernard Lyon 1 University, Lyon, France.

出版信息

Dermatol Ther. 2022 Aug;35(8):e15634. doi: 10.1111/dth.15634. Epub 2022 Jun 28.

DOI:10.1111/dth.15634
PMID:35695215
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9539986/
Abstract
摘要

相似文献

1
Long-term disease control and safety with the anti-CCR4 antibody mogamulizumab: Post-hoc analyses from the MAVORIC trial of patients with previously treated cutaneous T-cell lymphoma.抗CCR4抗体莫格利珠单抗用于长期疾病控制及安全性：来自MAVORIC试验中既往接受治疗的皮肤T细胞淋巴瘤患者的事后分析
Dermatol Ther. 2022 Aug;35(8):e15634. doi: 10.1111/dth.15634. Epub 2022 Jun 28.
2
Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection.聚焦莫格利珠单抗 - Kpkc 在成人复发或难治性蕈样真菌病或塞扎里综合征中的应用：疗效、安全性和患者选择。
Drug Des Devel Ther. 2020 Sep 16;14:3747-3754. doi: 10.2147/DDDT.S185896. eCollection 2020.
3
Cutaneous T-Cell Lymphoma: Optimizing Care in Patients Receiving Anti-CCR4 Monoclonal Antibody Mogamulizumab.皮肤T细胞淋巴瘤：优化接受抗CCR4单克隆抗体莫格利珠单抗治疗患者的护理
Clin J Oncol Nurs. 2019 Aug 1;23(4):E73-E80. doi: 10.1188/19.CJON.E73-E80.
4
Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial.MAVORIC 试验中，既往治疗的类型和范围对皮肤 T 细胞淋巴瘤患者 mogamulizumab 治疗结局无影响。
Leuk Lymphoma. 2021 Dec;62(13):3109-3118. doi: 10.1080/10428194.2021.1953007. Epub 2021 Jul 26.
5
Resistance to mogamulizumab is associated with loss of CCR4 in cutaneous T-cell lymphoma.对 mogamulizumab 的耐药性与皮肤 T 细胞淋巴瘤中 CCR4 的缺失有关。
Blood. 2022 Jun 30;139(26):3732-3736. doi: 10.1182/blood.2021014468.
6
Failure of second challenge with mogamulizumab in C-C chemokine receptor 4-positive cutaneous T-cell lymphoma.莫加莫拉单抗对C-C趋化因子受体4阳性皮肤T细胞淋巴瘤进行二次激发治疗失败。
Br J Dermatol. 2024 May 17;190(6):920-921. doi: 10.1093/bjd/ljae085.
7
Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas.莫格利珠单抗：一种用于 T 细胞淋巴瘤的抗 CC 趋化因子受体 4 抗体。
Ann Pharmacother. 2020 Apr;54(4):371-379. doi: 10.1177/1060028019884863. Epub 2019 Oct 25.
8
A drug safety evaluation of mogamulizumab for the treatment of cutaneous T-Cell lymphoma.莫格利珠单抗治疗皮肤 T 细胞淋巴瘤的药物安全性评价。
Expert Opin Drug Saf. 2019 Sep;18(9):769-776. doi: 10.1080/14740338.2019.1643837. Epub 2019 Jul 17.
9
Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma.多中心 II 期研究莫格利珠单抗（KW-0761），一种去岩藻糖基化的抗 CC 趋化因子受体 4 抗体，用于治疗复发的外周 T 细胞淋巴瘤和皮肤 T 细胞淋巴瘤患者。
J Clin Oncol. 2014 Apr 10;32(11):1157-63. doi: 10.1200/JCO.2013.52.0924. Epub 2014 Mar 10.
10
Mogamulizumab benefits seen in cutaneous T-cell lymphoma.在皮肤T细胞淋巴瘤中观察到莫加莫利单抗的疗效。
Lancet Oncol. 2015 May;16(5):e200. doi: 10.1016/S1470-2045(15)70143-9. Epub 2015 Mar 27.

引用本文的文献

1
Pharmacovigilance study for the identification of mogamulizumab-induced immune-related adverse events using a real-world database.利用真实世界数据库进行的用于识别莫加莫拉单抗诱导的免疫相关不良事件的药物警戒研究。
Oncologist. 2025 Jul 4;30(7). doi: 10.1093/oncolo/oyaf201.
2
Mogamulizumab and Concomitant Hypofractionated Low-Dose Total Skin Electron Beam Therapy (2 × 4 Gy) in Cutaneous T-Cell Lymphoma: Proof of Principle, Report of Two Cases.莫格利珠单抗联合低分割小剂量全身电子束照射（2×4Gy）治疗皮肤 T 细胞淋巴瘤：初步研究，两例报告。
Curr Oncol. 2024 Sep 13;31(9):5412-5421. doi: 10.3390/curroncol31090400.
3
CCL17, CCL22 and their receptor CCR4 in hematologic malignancies.血液系统恶性肿瘤中的CCL17、CCL22及其受体CCR4
Discov Oncol. 2024 Sep 6;15(1):412. doi: 10.1007/s12672-024-01210-x.
4
An occurrence of eosinophilic folliculitis and alopecia associated with a sustained complete response to mogamulizumab in Sézary syndrome: a case report.1例蕈样肉芽肿综合征中出现嗜酸性毛囊炎和脱发，对莫加莫珠单抗持续完全缓解：病例报告
Ther Adv Hematol. 2024 Mar 6;15:20406207241235777. doi: 10.1177/20406207241235777. eCollection 2024.

本文引用的文献

1
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.莫格利珠单抗对比伏立诺他治疗既往治疗的皮肤 T 细胞淋巴瘤（MAVORIC）：一项国际性、开放性标签、随机、对照的 3 期临床试验。
Lancet Oncol. 2018 Sep;19(9):1192-1204. doi: 10.1016/S1470-2045(18)30379-6. Epub 2018 Aug 9.
2
Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer.蕈样肉芽肿和塞扎里综合征的临床终点和反应标准：国际皮肤淋巴瘤学会、美国皮肤淋巴瘤联盟以及欧洲癌症研究与治疗组织皮肤淋巴瘤工作组的共识声明。
J Clin Oncol. 2011 Jun 20;29(18):2598-607. doi: 10.1200/JCO.2010.32.0630. Epub 2011 May 16.